Posted by Michael Wonder on 29 Apr 2019
PHARMAC proposes to give more clarity about funding decisions
29 April 2019 - An overhaul of PHARMAC’s decision-making process will give better insight into what medicines are - and are not - being actively considered for funding, Chief Executive, Sarah Fitt says.
Up until now there have been a number of funding applications that are unlikely to be funded but have remained open in the application system, so PHARMAC is proposing to decline them.
“We have open applications for medicines with little or no evidence that they work better than other medicines, with proof that they could cause people harm, or with no company able to supply the medicine in New Zealand,” says Ms Fitt.
